vorolanib   Click here for help

GtoPdb Ligand ID: 11618

Synonyms: CM-082 | CM082 | Example 8 [WO2008033562A2] | EYP-1901 | X-82
Compound class: Synthetic organic
Comment: Vorolanib (CM082) is a potent and selective, oral clinical stage multi-kinase inhibitor. Targets include all VEGFR isoforms, PDGFR and CSF1R. [1-3]. It is a structural derivative of sunitinib. Vorolanib has anti-angiogenic activity, and is being investigated for anti-tumour effects and utility to treat ocular neovascularisation.
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 7
Hydrogen bond donors 3
Rotatable bonds 6
Topological polar surface area 97.54
Molecular weight 439.2
XLogP 1.85
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES Fc1ccc2c(c1)/C(=C/c1[nH]c(c(c1C)C(=O)N[C@H]1CCN(C1)C(=O)N(C)C)C)/C(=O)N2
Isomeric SMILES Fc1ccc2c(c1)/C(=C/c1[nH]c(c(c1C)C(=O)N[C@H]1CCN(C1)C(=O)N(C)C)C)/C(=O)N2
InChI InChI=1S/C23H26FN5O3/c1-12-19(10-17-16-9-14(24)5-6-18(16)27-21(17)30)25-13(2)20(12)22(31)26-15-7-8-29(11-15)23(32)28(3)4/h5-6,9-10,15,25H,7-8,11H2,1-4H3,(H,26,31)(H,27,30)/b17-10-/t15-/m0/s1
InChI Key KMIOJWCYOHBUJS-HAKPAVFJSA-N
References
1. Dan H, Lei X, Huang X, Ma N, Xing Y, Shen Y. (2021)
CM082, a novel VEGF receptor tyrosine kinase inhibitor, can inhibit angiogenesis in vitro and in vivo.
Microvasc Res, 136: 104146. [PMID:33610563]
2. Liang C, Gao S, Li X. (2008)
Kinase inhibitor compounds.
Patent number: WO2008033562A2. Assignee: Xcovery, Inc.. Priority date: 15/09/2006. Publication date: 20/03/2008.
3. Ren C, Shi H, Jiang J, Liu Q, Du Y, He M, Cai W, Wei Q, Yu J. (2017)
The Effect of CM082, an Oral Tyrosine Kinase Inhibitor, on Experimental Choroidal Neovascularization in Rats.
J Ophthalmol, 2017: 6145651. [PMID:29201457]
4. Sheng X, Yan X, Chi Z, Cui C, Si L, Tang B, Li S, Mao L, Lian B, Wang X et al.. (2020)
Phase 1 trial of vorolanib (CM082) in combination with everolimus in patients with advanced clear-cell renal cell carcinoma.
EBioMedicine, 55: 102755. [PMID:32335374]
5. Song Y, Wang J, Ren X, Jin J, Mao L, Liang C, Ding L, Yang L. (2021)
Vorolanib, an oral VEGFR/PDGFR dual tyrosine kinase inhibitor for treatment of patients with advanced solid tumors: An open-label, phase I dose escalation and dose expansion trial.
Chin J Cancer Res, 33 (1): 103-114. [PMID:33707933]